Francesco Luzzaro

List of Publications by Year in descending order

112 papers	4,543 citations	109321 35 h-index	110387 64 g-index
116 all docs	116 docs citations	116 times ranked	4666 citing authors

#	Article	IF	Citations
1	CTX-M: changing the face of ESBLs in Europe. Journal of Antimicrobial Chemotherapy, 2006, 59, 165-174.	3.0	756
2	Occurrence of Extended-Spectrum Î²-Lactamases in Members of the Family Enterobacteriaceae in Italy: Implications for Resistance to Î²-Lactams and Other Antimicrobial Drugs. Antimicrobial Agents and Chemotherapy, 2002, 46, 196-202.	3.2	144
3	Metallo-Î²-lactamases as emerging resistance determinants in Gram-negative pathogens: open issues. International Journal of Antimicrobial Agents, 2007, 29, 380-388.	2.5	134
4	Proteus mirabilis Bloodstream Infections: Risk Factors and Treatment Outcome Related to the Expression of Extended-Spectrum Î²-Lactamases. Antimicrobial Agents and Chemotherapy, 2005, 49, 2598-2605.	3.2	130
5	IMP-12, a New Plasmid-Encoded Metallo-Î²-Lactamase from a Pseudomonas putida Clinical Isolate. Antimicrobial Agents and Chemotherapy, 2003, 47, 1522-1528.	3.2	125
6	Molecular Characterization of Extended-Spectrum Â-Lactamases Produced by Nosocomial Isolates of Enterobacteriaceae from an Italian Nationwide Survey. Journal of Clinical Microbiology, 2002, 40, 611-614.	3.9	116
7	Trends in Production of Extended-Spectrum Î²-Lactamases among Enterobacteria of Medical Interest: Report of the Second Italian Nationwide Survey. Journal of Clinical Microbiology, 2006, 44, 1659-1664.	3.9	110
8	CTX-M-Type Extended-Spectrum Î²-Lactamases in Italy: Molecular Epidemiology of an Emerging Countrywide Problem. Antimicrobial Agents and Chemotherapy, 2006, 50, 2700-2706.	3.2	107
9	Nosocomial Infections Caused by Multidrug-Resistant Isolates of Pseudomonas putida Producing VIM-1 Metallo-Î²-Lactamase. Journal of Clinical Microbiology, 2002, 40, 4051-4055.	3.9	105
10	Bacteremia Due toKlebsiella pneumoniaeIsolates Producing the TEMâ€52 Extendedâ€Spectrum Î²â€Lactamase: Treatment Outcome of Patients Receiving Imipenem or Ciprofloxacin. Clinical Infectious Diseases, 2004, 38, 243-251.	5.8	105
11	Characterization of pABVA01, a Plasmid Encoding the OXA-24 Carbapenemase from Italian Isolates of Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 2009, 53, 3528-3533.	3.2	105
12	Emergence in Klebsiella pneumoniae and Enterobacter cloacae Clinical Isolates of the VIM-4 Metallo-Î²-Lactamase Encoded by a Conjugative Plasmid. Antimicrobial Agents and Chemotherapy, 2004, 48, 648-650.	3.2	103
13	Evolution of CTX-M-type Î²-lactamases in isolates of Escherichia coli infecting hospital and community patients. International Journal of Antimicrobial Agents, 2005, 25, 157-162.	2.5	94
14	FIM-1, a New Acquired Metallo-Î²-Lactamase from a Pseudomonas aeruginosa Clinical Isolate from Italy. Antimicrobial Agents and Chemotherapy, 2013, 57, 410-416.	3.2	87
15	Dynamics of a Nosocomial Outbreak of Multidrug-Resistant Pseudomonas aeruginosa Producing the PER-1 Extended-Spectrum Î²-Lactamase. Journal of Clinical Microbiology, 2001, 39, 1865-1870.	3.9	74
16	First Detection of the mcr-1 Colistin Resistance Gene in Escherichia coli in Italy. Antimicrobial Agents and Chemotherapy, 2016, 60, 3257-3258.	3.2	74
17	The Revival of Aztreonam in Combination with Avibactam against Metallo-Î²-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases. Antibiotics, 2021, 10, 1012.	3.7	73
18	Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers. Journal of Antimicrobial Chemotherapy, 2018, 73, 664-671.	3.0	71

#	Article	IF	Citations
19	In Vitro Activity of the Novel Antimicrobial Peptide Dendrimer G3KL against Multidrug-Resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2015, 59, 7915-7918.	3.2	70
20	Prevalence and epidemiology of microbial pathogens causing bloodstream infections: results of the OASIS multicenter study. Diagnostic Microbiology and Infectious Disease, 2011, 69, 363-369.	1.8	69
21	CMY-16, a Novel Acquired AmpC-Type Î²-Lactamase of the CMY/LAT Lineage in Multifocal Monophyletic Isolates of Proteus mirabilis from Northern Italy. Antimicrobial Agents and Chemotherapy, 2006, 50, 618-624.	3.2	68
22	Epidemic Diffusion of OXA-23-Producing Acinetobacter baumannii Isolates in Italy: Results of the First Cross-Sectional Countrywide Survey. Journal of Clinical Microbiology, 2014, 52, 3004-3010.	3.9	64
23	Resistance to ceftazidime/avibactam in infections and colonisations by KPC-producing Enterobacterales: a systematic review of observational clinical studies. Journal of Global Antimicrobial Resistance, 2021, 25, 268-281.	2.2	62
24	First Countrywide Survey of Acquired Metallo-Î²-Lactamases in Gram-Negative Pathogens in Italy. Antimicrobial Agents and Chemotherapy, 2008, 52, 4023-4029.	3.2	58
25	Epidemiology and genetic characteristics of extended-spectrum Â-lactamase-producing Gram-negative bacteria causing urinary tract infections in long-term care facilities. Journal of Antimicrobial Chemotherapy, 2012, 67, 2982-2987.	3.0	58
26	Spread of multidrug-resistant Proteus mirabilis isolates producing an AmpC-type Î²-lactamase: epidemiology and clinical management. International Journal of Antimicrobial Agents, 2009, 33, 328-333.	2.5	51
27	Evolving beta-lactamase epidemiology in Enterobacteriaceae from Italian nationwide surveillance, October 2013: KPC-carbapenemase spreading among outpatients. Eurosurveillance, 2017, 22, .	7.0	49
28	Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of Î²-lactam/Î²-lactamase inhibitor combinations. International Journal of Antimicrobial Agents, 2001, 17, 131-135.	2.5	46
29	PER-1 Extended-Spectrum Î²-Lactamase Production in anAlcaligenes faecalisClinical Isolate Resistant to Expanded-Spectrum Cephalosporins and Monobactams from a Hospital in Northern Italy. Microbial Drug Resistance, 2000, 6, 85-90.	2.0	45
30	Management of carbapenem resistant Klebsiella pneumoniae infections in stem cell transplant recipients: an Italian multidisciplinary consensus statement. Haematologica, 2015, 100, e373-e376.	3.5	44
31	An allelic variant of the PmrB sensor kinase responsible for colistin resistance in an Escherichia coli strain of clinical origin. Scientific Reports, 2017, 7, 5071.	3.3	42
32	Multidrug-ResistantPseudomonas aeruginosaProducing PER-1 Extended-Spectrum Serine-Î²-Lactamase and VIM-2 Metallo-Î²-Lactamase. Emerging Infectious Diseases, 2001, 7, 910-911.	4.3	40
33	Novel 3- N -Aminoglycoside Acetyltransferase Gene, aac (3)- Ic , from a Pseudomonas aeruginosa Integron. Antimicrobial Agents and Chemotherapy, 2003, 47, 1746-1748.	3.2	40
34	Pseudomonas aeruginosa bloodstream infections: risk factors and treatment outcome related to expression of the PER-1 extended-spectrum beta-lactamase. BMC Infectious Diseases, 2006, 6, 52.	2.9	40
35	Spread in an Italian Hospital of a Clonal Acinetobacter baumannii Strain Producing the TEM-92 Extended-Spectrum Î²-Lactamase. Antimicrobial Agents and Chemotherapy, 2007, 51, 2211-2214.	3.2	39
36	Cross-Infection of Solid Organ Transplant Recipients by a Multidrug-Resistant Klebsiella pneumoniae Isolate Producing the OXA-48 Carbapenemase, Likely Derived from a Multiorgan Donor. Journal of Clinical Microbiology, 2014, 52, 2702-2705.	3.9	38

#	Article	IF	Citations
37	Diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infective Therapy (SITA), the Italian Group for Antimicrobial Stewardship (GISA), the Italian Association of Clinical Microbiologists (AMCLI) and the Italian Society of Microbiology (SIM). International Journal of Antimicrobial Agents, 2022, 60, 106611.	2.5	36
38	Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and Â-haemolytic streptococci collected from western European countries in 2011. Journal of Antimicrobial Chemotherapy, 2013, 68, 164-167.	3.0	35
39	Characterization of a new TEM-derived beta-lactamase produced in a Serratia marcescens strain. Antimicrobial Agents and Chemotherapy, 1997, 41, 2374-2382.	3.2	34
40	Emergence and spread of a multidrug-resistant Acinetobacter baumannii clone producing both the carbapenemase OXA-23 and the 16S rRNA methylase ArmA. Journal of Medical Microbiology, 2012, 61, 653-661.	1.8	34
41	Use of the Phoenix Automated System for Identification of Streptococcus and Enterococcus spp.. Journal of Clinical Microbiology, 2006, 44, 3263-3267.	3.9	33
42	Evaluation of a New Commercial Microarray Platform for the Simultaneous Detection of Î²-Lactamase and mcr-1 and mcr-2 Genes in Enterobacteriaceae. Journal of Clinical Microbiology, 2017, 55, 3138-3141.	3.9	33
43	Prevalence and characterization of metallo-Î²-lactamases in clinical isolates of pseudomonas aeruginosaâ˜†. Diagnostic Microbiology and Infectious Disease, 2004, 48, 131-135.	1.8	31
44	Characterization of the IncA/C plasmid pCC416 encoding VIM-4 and CMY-4 Î²-lactamases. Journal of Antimicrobial Chemotherapy, 2007, 60, 258-262.	3.0	30
45	Characterization of resistance mechanisms and genetic relatedness of carbapenem-resistant Acinetobacter baumannii isolated from blood, Italy. Diagnostic Microbiology and Infectious Disease, 2013, 75, 180-186.	1.8	30
46	Comparing BioFire FilmArray BCID2 and BCID Panels for Direct Detection of Bacterial Pathogens and Antimicrobial Resistance Genes from Positive Blood Cultures. Journal of Clinical Microbiology, 2021, 59, .	3.9	30
47	Burkholderia cepacia complex in cystic fibrosis and non-cystic fibrosis patients: identification of a cluster of epidemic lineages. Journal of Hospital Infection, 2002, 50, 188-195.	2.9	29
48	A two-year analysis of risk factors and outcome in patients with bloodstream infection. Japanese Journal of Infectious Diseases, 2003, 56, 1-7.	1.2	28
49	Review on colonization of residents and staff in Italian long-term care facilities by multidrug-resistant bacteria compared with other European countries. Antimicrobial Resistance and Infection Control, 2016, 5, 33.	4.1	27
50	Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia. BMC Infectious Diseases, 2005, 5, 106.	2.9	26
51	Escherichia coli ST131 Producing Extended-Spectrum Â-Lactamases Plus VIM-1 Carbapenemase: Further Narrowing of Treatment Options. Clinical Infectious Diseases, 2011, 52, 690-691.	5.8	26
52	Simplified Testing Method for Direct Detection of Carbapenemase-Producing Organisms from Positive Blood Cultures Using the NG-Test Carba 5 Assay. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	26
53	Evaluation of the peptide nucleic acid fluorescence in situ hybridisation technology for yeast identification directly from positive blood cultures: an Italian experience. Mycoses, 2012, 55, 388-392.	4.0	25
54	Clonal Diversity and Metallo-Î²-Lactamase Production in Clinical Isolates ofStenotrophomonas maltophilia. Microbial Drug Resistance, 2002, 8, 193-200.	2.0	23

#	Article	IF	Citations
55	Erysipelothrix rhusiopathiae Bacteremia without Endocarditis: Rapid Identification from Positive Blood Culture by MALDI-TOF Mass Spectrometry. A Case Report and Literature Review. Gastroenterology Insights, 2016, 8, 6368.	1.2	23
56	Rapid Increase of CTX-M-Producing Shigella sonnei Isolates in Switzerland Due to Spread of Common Plasmids and International Clones. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	22
57	Necrotizing Pneumonitis and Empyema Caused by Streptococcus cremoris from Milk. Scandinavian Journal of Infectious Diseases, 1990, 22, 221-222.	1.5	20
58	First report of NDM-1-producing Klebsiella pneumoniae imported from Africa to Italy: Evidence of the need for continuous surveillance. Journal of Global Antimicrobial Resistance, 2017, 8, 23-27.	2.2	20
59	Incidence of SARS-CoV-2 infection in health care workers from Northern Italy based on antibody status: immune protection from secondary infection- A retrospective observational case-controlled study. International Journal of Infectious Diseases, 2021, 109, 199-202.	3.3	20
60	Comparison of the in-house made Carba-NP and Blue-Carba tests: Considerations for better detection of carbapenemase-producing Enterobacteriaceae. Journal of Microbiological Methods, 2016, 122, 33-37.	1.6	19
61	Multicenter prospective study on the prevalence of colistin resistance in Escherichia coli: relevance of mcr-1-positive clinical isolates in Lombardy, Northern Italy. Infection and Drug Resistance, 2018, Volume 11, 377-385.	2.7	19
62	KPC-53, a KPC-3 Variant of Clinical Origin Associated with Reduced Susceptibility to Ceftazidime-Avibactam. Antimicrobial Agents and Chemotherapy, 2020, 65, .	3.2	19
63	Dissemination of CTX-M-Type Extended-Spectrum Î²-Lactamase Genes to Unusual Hosts. Journal of Clinical Microbiology, 2005, 43, 4183-4185.	3.9	18
64	Direct identification of microorganisms from positive blood cultures using the lysis-filtration technique and matrix assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS): a multicentre study. New Microbiologica, 2015, 38, 245-50.	0.1	18
65	Zinc Chelators as Carbapenem Adjuvants for Metallo-Î²-Lactamase-Producing Bacteria: In Vitro and In Vivo Evaluation. Microbial Drug Resistance, 2020, 26, 1133-1143.	2.0	17
66	Novel TEM-Type Extended-Spectrum Î²-Lactamase, TEM-134, in a Citrobacter koseri Clinical Isolate. Antimicrobial Agents and Chemotherapy, 2005, 49, 1564-1566.	3.2	15
67	Mother-To-Child Transmission of KPC Carbapenemase-Producing Klebsiella Pneumoniae at Birth. Pediatric Infectious Disease Journal, 2017, 36, 228-229.	2.0	15
68	Role of place of acquisition and inappropriate empirical antibiotic therapy on the outcome of extended-spectrum Î²-lactamase-producing Enterobacteriaceae infections. International Journal of Antimicrobial Agents, 2019, 54, 49-54.	2.5	15
69	Comparative Activity of Piperacillin/Tazobactam against Clinical Isolates of Extended- Spectrum Î²-Lactamase-Producing Enterobacteriaceae. Chemotherapy, 1998, 44, 377-384.	1.6	14
70	Identification by mass spectrometry and automated susceptibility testing from positive bottles: a simple, rapid, and standardized approach to reduce the turnaround time in the management of blood cultures. BMC Infectious Diseases, 2017, 17, 749.	2.9	14
71	Spread of Enterobacteriaceae carrying the PER-1 extended-spectrum Â-lactamase gene as a chromosomal insert: a report from Italy. Journal of Antimicrobial Chemotherapy, 2006, 59, 323-324.	3.0	13
72	Zidovudine in synergistic combination with fosfomycin: an in vitro and in vivo evaluation against multidrug-resistant Enterobacterales. International Journal of Antimicrobial Agents, 2021, 58, 106362.	2.5	13

#	Article	IF	Citations
73	Antimicrobial Activity of Aztreonam in Combination with Old and New Î²-Lactamase Inhibitors against MBL and ESBL Co-Producing Gram-Negative Clinical Isolates: Possible Options for the Treatment of Complicated Infections. Antibiotics, 2021, 10, 1341.	3.7	13
74	Anaerobic bloodstream infections in Italy (ITANAEROBY): A 5-year retrospective nationwide survey. Anaerobe, 2022, 75, 102583.	2.1	13
75	Performance in detection and reporting Î²-lactam resistance phenotypes in Enterobacteriaceae: a nationwide proficiency study in Italian laboratories. Diagnostic Microbiology and Infectious Disease, 2006, 55, 311-318.	1.8	12
76	Persistence of TEM-52/TEM-92 and SHV-12 Extended-Spectrum Î²-Lactamases in Clinical Isolates of Enterobacteriaceae in Italy. Microbial Drug Resistance, 2011, 17, 521-524.	2.0	12
77	Deciphering the complete deletion of the mgrB locus in an unusual colistin-resistant Klebsiella pneumoniae isolate colonising the gut of a traveller returning from India. International Journal of Antimicrobial Agents, 2018, 51, 529-531.	2.5	12
78	Results of the Italian infection-Carbapenem Resistance Evaluation Surveillance Trial (iCREST-IT): activity of ceftazidime/avibactam against Enterobacterales isolated from urine. Journal of Antimicrobial Chemotherapy, 2020, 75, 979-983.	3.0	12
79	Epidemiology of bloodstream infections and time to detection of positive blood cultures: an evaluation of the automated BacT/Alert and BACTEC 9240 systems. New Microbiologica, 2002, 25, 9-16.	0.1	12
80	Acquisition of plasmid-borne blaIMP-19 gene by a VIM-1-positive Pseudomonas aeruginosa of the sequence type 235 epidemic lineage. Journal of Antimicrobial Chemotherapy, 2013, 68, 722-724.	3.0	11
81	Recommendations for the surveillance of multidrug-resistant bacteria in Italian long-term care facilities by the GLISTer working group of the Italian Association of Clinical Microbiologists (AMCLI). Antimicrobial Resistance and Infection Control, 2020, 9, 106.	4.1	11
82	Whole-Genome Sequence of the First Extended-Spectrum Î²-Lactamase-Producing Strain of Salmonella enterica subsp. enterica Serovar Napoli. Microbiology Resource Announcements, 2018, 7, .	0.6	10
83	Evaluation of EDTA- and DPA-Based Microdilution Phenotypic Tests for the Detection of MCR-Mediated Colistin Resistance in Enterobacteriaceae. Microbial Drug Resistance, 2019, 25, 494-500.	2.0	10
84	Microarray technology for yeast identification directly from positive blood cultures. A multicenter Italian experience. Medical Mycology, 2012, 50, 549-555.	0.7	9
85	Extended-Spectrum Î²-Lactamases Conferring Resistance to Monobactams and Oxyimino-Cephalosporins in Clinical Isolates ofSerratia marcescens. Journal of Chemotherapy, 1995, 7, 175-178.	1.5	8
86	Microbiology of Postoperative Infections. Surgical Infections, 2006, 7, s-13-s-16.	1.4	8
87	Biochemical analysis of TEM-134, a new TEM-type extended-spectrum Â-lactamase variant produced in a Citrobacter koseri clinical isolate from an Italian hospital. Journal of Antimicrobial Chemotherapy, 2007, 60, 877-880.	3.0	8
88	Antimicrobial Susceptibility, Virulence, and Genomic Features of a Hypervirulent Serotype K2, ST65 Klebsiella pneumoniae Causing Meningitis in Italy. Antibiotics, 2022, 11, 261.	3.7	8
89	Drug susceptibility testing of clinical isolates of streptococci and enterococci by the Phoenix automated microbiology system. BMC Microbiology, 2007, 7, 46.	3.3	7
90	Polypyridine ligands as potential metallo-Î²-lactamase inhibitors. Journal of Inorganic Biochemistry, 2021, 215, 111315.	3.5	7

#	Article	IF	Citations
91	Whole-Genome Sequencing Investigation of a Large Nosocomial Outbreak Caused by ST131 H30Rx KPC-Producing Escherichia coli in Italy. Antibiotics, 2021, 10, 718.	3.7	7
92	Successful prolonged cefiderocol treatment of a chronic left pleural empyema caused by Pseudomonas aeruginosa in a patient affected by COVID-19: a case report. Journal of Global Antimicrobial Resistance, 2021, 27, 157-159.	2.2	7
93	Biochemical Characterization of TEM-92 Extended-Spectrum Î²-Lactamase, a Protein Differing from TEM-52 in the Signal Peptide. Antimicrobial Agents and Chemotherapy, 2002, 46, 3981-3983.	3.2	6
94	Characterisation of the first extended-spectrum Î²-lactamase (ESBL)-producing Shigella sonnei clinical isolate in Italy. Journal of Global Antimicrobial Resistance, 2019, 17, 58-59.	2.2	5
95	Trends in the Incidence and Antibiotic Resistance of Enterococcal Bloodstream Isolates: A 7-Year Retrospective Multicenter Epidemiological Study in Italy. Microbial Drug Resistance, 2021, 27, 529-535.	2.0	5
96	The humoral immune response to SARS-CoV-2 mounts and is durable in symptomatic haemodialysis patients. Nephrology Dialysis Transplantation, 2021, 36, 1132-1134.	0.7	5
97	Evaluation of brilliance CRE agar for the detection of carbapenem-resistant gram-negative bacteria. New Microbiologica, 2013, 36, 181-6.	0.1	5
98	The EDTA-based disk-combination tests are unreliable for the detection of MCR-mediated colistin-resistance in Enterobacteriaceae. Journal of Microbiological Methods, 2018, 153, 31-34.	1.6	4
99	In vitroactivity of ceftazidime/avibactam against clinical isolates of ESBL-producingEnterobacteriaceaein Italy. Journal of Chemotherapy, 2019, 31, 195-201.	1.5	4
100	Reporting epidemiology of antibiotic resistance. Microbiologia Medica, 2015, 30, .	0.1	3
101	Emergence of Haemophilus parainfluenzae resistant to third-generation cephalosporins in Italy: potential role of PBP3 and PBP5 substitutions in high-level resistance. International Journal of Antimicrobial Agents, 2020, 56, 106159.	2.5	3
102	Humoral and T-cell response to SARS-CoV-2 mRNA BNT162b2 vaccination in a cohort of kidney transplant recipients and their cohabitant living kidney donor partners. CKJ: Clinical Kidney Journal, 2022, 15, 820-821.	2.9	3
103	Simultaneous gut colonization by Klebsiella grimontii and Escherichia coli co-possessing the blaKPC-3-carrying pQil plasmid. European Journal of Clinical Microbiology and Infectious Diseases, 2022, 41, 1087-1091.	2.9	3
104	Diagnostica delle ÃŸ-lattamasi a spettro esteso (ESBL) nelle Enterobacteriaceae: problemi e raccomandazioni nella realtÃ epidemiologica italiana. Microbiologia Medica, 2007, 22, .	0.1	2
105	Mother-to-child transmission of KPC-producing Klebsiella pneumoniae : potential relevance of a low microbial urinary load for screening purposes. Journal of Hospital Infection, 2018, 98, 314-316.	2.9	2
106	Emergence of CTX-M-1-producing Salmonella enterica serovar Napoli: A novel â€˜enzymeâ€“pathogen associationâ€™ in the Italian extended-spectrum Î²-lactamase (ESBL) endemic context. Journal of Global Antimicrobial Resistance, 2018, 15, 101-102.	2.2	2
107	Novel vanA-carrying plasmid in a clinical isolate of Enterococcus avium. International Journal of Antimicrobial Agents, 2019, 53, 876-877.	2.5	2
108	EUCAST rapid antimicrobial susceptibility testing of blood cultures positive for Escherichia coli or Klebsiella pneumoniae: experience of three laboratories in Italy. Journal of Antimicrobial Chemotherapy, 2021, 76, 1110-1112.	3.0	2

#	Article	IF	Citations
109	A Two Amino Acid Duplication, L167E168, in the Î©-Loop Drastically Decreases Carbapenemase Activity of KPC-53, a Natural Class A Î²-Lactamase. Antimicrobial Agents and Chemotherapy, 2022, 66, .	3.2	2
110	An XDR Proteus vulgaris isolate hosting a novel blaNDM-1- and armA-carrying plasmid. Journal of Antimicrobial Chemotherapy, 2021, 76, 1938-1941.	3.0	1
111	Evaluation of the in vitro activity of ceftobiprole against clinical isolates of Staphylococcus aureus. Microbiologia Medica, 2016, 31, .	0.1	0
112	Sustained humoral response 6 months after the anti-SARS-CoV-2 mRNA-BNT162b2 vaccine in haemodialysis patients: should booster vaccine doses be given to all patients at the same time?. CKJ: Clinical Kidney Journal, 2022, 15, 1012-1014.	2.9	0